Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Mitsubishi Chemical Medience Begins Contract Synthesis of Radiolabeled Compounds
August 29, 2011
- Emerging Markets, Japan Drove Growth in 1st Half of 2011 for Global Megapharmas
August 29, 2011
- Hisamitsu to Apply for Transdermal Oxybutynin for OAB in FY2012
August 29, 2011
- Seikagaku to Conduct Add'l Clinical Trial for SI-6603 in Japan
August 29, 2011
- Drug Wholesalers' Operating Profit Rate at Record Low 0.13% in FY2010: JPWA
August 29, 2011
- Chugai Files Application for Add'l Indication for Kytril Based on Data in Public Domain
August 29, 2011
- Kyowa Kirin Initiates PIII Trial of ARQ197 for NSCLC in Asian Countries
August 29, 2011
- Teijin Pharma, Astellas Sign New Marketing Agreement on Febuxostat
August 29, 2011
- Astellas, Kyowa Kirin Apply for Higher Doses of Amoxicillin Based on Data in Public Domain
August 29, 2011
- AnGes MG Granted Pharmaceutical Use Patent for Ets-1 in US
August 29, 2011
- NCVC to Expand Infrastructure for 1st-in-human Studies for Medical Devices
August 15, 2011
- FIRM Starts Activities Creating 3 WGs
August 15, 2011
- Daiichi Sankyo to Expand Hybrid Business Model in Mexico
August 15, 2011
- Combination Drugs Are Part of Innovation: Prof. Kaku of Kawasaki Medical School
August 15, 2011
- Statistics
August 15, 2011
- DSP Not Planning Full-scale Entry into Generic Business: President Tada
August 15, 2011
- Korosho Forecasts 92,000 Patients Admitted for Dementia in 2026
August 15, 2011
- Korosho's Study Group Proposes Qualifications for GMP Inspectors
August 15, 2011
- Fuji Pharma: Sales Up 7% Driven by Hormonal Drugs
August 15, 2011
- M3 Survey of Doctors Finds Differences in Ways Companies Detail AD Treatments
August 15, 2011
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…